Trial
NCT04049266
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Kodiak Sciences Inc
Collaborators
—
Condition
Wet Macular Degeneration
Intervention
KSI-301
Why stopped
Primary Endpoint Not Met
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-18